Brexit deal gives MHRA ample room to innovate

With a thirteenth hour trade agreement putting the four-year-long Brexit ordeal in the rearview mirror, the U.K. now has the independence to cut a new path as a regulatory innovator while its scientists retain access to Europe’s largest research and innovation program.

The COVID-19 pandemic has already given the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) an opportunity to showcase its chops as a regulatory leader.  ...